血清识别高危MASH:代谢组学-晚期脂肪性肝炎纤维化评分(MASEF)
研究基于国际多中心队列开发并验证了由12种脂质、体重指数、天冬氨酸氨基转移酶和丙氨酸氨基转移酶构成的MASEF评分,用于识别高危代谢功能障碍相关脂肪性肝炎(MASH)。推导队列(n=790)和验证队列(n=565)中MASEF的AUC分别为0.76和0.79,验证队列中与FibroScan-AST评分比较AUC差异未达统计学显著(p=0.064)。FIB-4+MASEF与FIB-4+振动控制瞬时弹性成像肝硬度检测识别高危MASH的总体性能相似(p=0.69)。
要点
- MASEF评分由12种脂质、BMI、AST和ALT构成,用于识别高危MASH。
- 验证队列中MASEF的AUC为0.79(95%CI 0.75-0.83),FibroScan-AST为0.74(95%CI 0.68-0.79;p=0.064)。
- FIB-4+MASEF与FIB-4+LSM识别高危MASH的总体性能相似(p=0.69)。
核心结论
- MASEF是评估高危MASH有前景的诊断工具,可在目前多个指南推荐的流程中替代VCTE检测的LSM。
研究设计与样本
- 研究纳入来自国际三级中心的推导队列(n=790)和验证队列(n=565),患者接受实验室评估和肝活检以诊断代谢功能障碍相关脂肪性肝病。
主要发现
- 推导队列中MASEF诊断高危MASH的AUC为0.76(95%CI 0.72-0.79),灵敏度0.69,特异度0.74,阳性预测值0.53,阴性预测值0.85。
- 验证队列中MASEF的AUC为0.79(95%CI 0.75-0.83),灵敏度0.78,特异度0.65,阳性预测值0.48,阴性预测值0.88。
- 验证队列中FibroScan-AST的AUC为0.74(95%CI 0.68-0.79;p=0.064),灵敏度0.58,特异度0.79,阳性预测值0.67,阴性预测值0.73。
- FIB-4+MASEF与FIB-4+VCTE检测的LSM识别高危MASH的总体性能相似(p=0.69)。
关键数值与推荐
- MASEF评分基于12种脂质、体重指数、天冬氨酸氨基转移酶和丙氨酸氨基转移酶构建,用于识别高危MASH。
- 高危MASH定义为NAFLD活动度评分≥4且显著纤维化(≥F2)。
临床怎么用
- MASEF是有前景的诊断工具,可在目前多个指南推荐的流程中替代VCTE检测的LSM。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early identification of those with NAFLD activity score ≥ 4 and significant fibrosis (≥F2) or at-risk metabolic dysfunction-associated steatohepatitis (MASH) is a priority as these patients are at increased risk for disease progression and may benefit from therapies. We developed and validated a highly specific metabolomics-driven score to identify at-risk MASH. METHODS: We included derivation (n = 790) and validation (n = 565) cohorts from international tertiary centers. Patients underwent laboratory assessment and liver biopsy for metabolic dysfunction-associated steatotic liver disease. Based on 12 lipids, body mass index, aspartate aminotransferase, and alanine aminotransferase, the MASEF score was developed to identify at-risk MASH and compared to the FibroScan-AST (FAST) score. We further compared the performance of a FIB-4 + MASEF algorithm to that of FIB-4 + liver stiffness measurements (LSM) by vibration-controlled transient elastography (VCTE). RESULTS: The diagnostic performance of the MASEF score showed an area under the receiver-operating characteristic curve, sensitivity, specificity, and positive and negative predictive values of 0.76 (95% CI 0.72-0.79), 0.69, 0.74, 0.53, and 0.85 in the derivation cohort, and 0.79 (95% CI 0.75-0.83), 0.78, 0.65, 0.48, and 0.88 in the validation cohort, while FibroScan-AST performance in the validation cohort was 0.74 (95% CI 0.68-0.79; p = 0.064), 0.58, 0.79, 0.67, and 0.73, respectively. FIB-4+MASEF showed similar overall performance compared with FIB-4 + LSM by VCTE ( p = 0.69) to identify at-risk MASH. CONCLUSION: MASEF is a promising diagnostic tool for the assessment of at-risk MASH. It could be used alternatively to LSM by VCTE in the algorithm that is currently recommended by several guidance publications.
引用
- Noureddin M, Truong E, Mayo R, et al. Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF). Hepatology. 2023. PMID: 37505221. doi:10.1097/HEP.0000000000000542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。